Global Pharmacovigilance Market

The pharma microbiology testing kits market consists of sales of pharma microbiology testing kits and related services. The pharma microbiology testing kits are used to detect the microbial limits among drugs, vaccines, and other biologics. The related services include only installation and maintenance services offered by equipment manufacturers. The main products of pharma microbiology testing kits are consumables and equipment. The pharma microbiology testing kits consumables are products used to detect the microbial limits among drugs, vaccines, and other biologics. The various tests performed by pharma microbiology testing kits are endotoxin testing, sterility testing, microbial examination, environmental monitoring, and others that are used by end-users such as hospitals and diagnostic centers, custom lab service providers, and academic and research institutes. The global pharma microbiology testing kits market size is expected to grow from $5.12 billion in 2021 to $5.66 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The global pharma microbiology testing kit market is expected to grow to $7.94 billion in 2026 at a CAGR of 8.8%. The rise in the incidence of infectious diseases is one of the prime drivers of the pharma microbiology testing kits market. According to CDC (Centre for Disease Control and Prevention), infectious diseases such as Hepatitis A, B, and C, sexually transmitted diseases (STDs), and human immunodeficiency virus (HIV) are increasing their prevalence globally. WHO report indicated that there were about 1.4 million cases of Hepatitis A reported globally every year. Hence the increasing number of infectious disease cases due to infected needle injections, unprotected sex, homelessness, lack of access to medical care, and other socioeconomic challenges drive the pharma microbiology testing kits market. The limited shelf life of microorganisms and microbiology reagents acts as a major restraint on the pharma microbiology testing kits market. Shelf life is defined as the time for which a product remains fit for use after its generation. The shelf life of microbiology reagents depends upon exposure to atmospheric conditions. The life of microorganisms such as bacteria (only 12hours) is short therefore the time for microbiological research is very limited as the quality of microorganisms deteriorates and becomes unfit to use resulting in inaccurate pharma microbiology testing kits results. Hence, the short or limited shelf life of microbiology reagents may increase cost and hamper the pharma microbiology testing kits market growth. Outsourcing of microbiological testing to contract testing laboratories is becoming popular in the pharma microbiology testing kits market. Outsourcing of routine microbiological testing activities controls and ensures better quality and safety of raw materials, intermediates, and finished products. The contract testing laboratories are outsourced with some testing areas such as stability testing, raw material testing, method validation, microbial testing, environmental monitoring, physical characterization, batch-release testing, bioanalytical testing, and others. For instance, the global healthcare analytical testing market is projected to expand to $4.13 billion by 2021 at a growth rate of 11.3%. Food and Drug Administration (FDA) is a federal agency and regulatory body for the pharma microbiology testing kits market in the United States department of health and human services. Laboratories and food companies across the globe use these standards to make sure that food products are safe to eat and drink. FDA's Bacteriological Analytical Manual (BAM) detects pathogens (bacterial, viral, parasitic, plus yeast and mold) in food and cosmetic products. Enhanced standards for microbial testing, additional microbiological methods, and environmental testing methods have been set by FDA to ensure food and drug safety. In February 2019, bioMérieux, a food microbiology testing and in vitro diagnostics company, acquired Invisible Sentinel for $75 million. This acquisition would strengthen and broaden bioMérieux's product portfolio with molecular diagnostic tools, and capitalize on marketing innovative technologies such as DNA Signature Capturing Technology. Invisible Sentinel manufactures and markets innovative molecular diagnostic tools for the rapid, accurate, and reliable detection of pathogens and spoilage organisms in food and beverage. Invisible Sentinel Inc. was founded in 2006 and is headquartered in Philadelphia, Pennsylvania, United States of America. Major players in the pharma microbiology testing kits market are F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Abbott Laboratories, ThermoFisher Scientific, Lucideon, SGS SA, ToxiKon, Pace Analytical Services, Boston Analytics, Charles River Laboratories International, and Nelson Laboratories. The regions covered in the global pharma microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharma microbiology testing kits market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global pharma microbiology testing kits market is segmented - 1) By Product: Consumables, Equipment 2) By Test: Endotoxin Testing, Sterility Testing, Microbial Examination, Environmental Monitoring, Others 3) By End User: Hospitals and Diagnostic Centers, Custom Lab Service Providers, Academic and Research Institutes

The pharmaceutical drug market consists of sales of goods and related services by entities (organizations, sole traders and partnerships) that produce and sell pharmaceutical drugs used to treat various diseases. This industry includes establishments that produce drugs such as cardiovascular drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs and other drugs used to treat cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global pharmaceutical drugs market size is expected to grow from $ 1,075.97 billion in 2021 to $1,136.23 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical drugs market is expected to reach $1,635.128 billion in 2026 at a CAGR of 9.5%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drugs market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research and development of new products. For instance, the US interest rates rose up to 3.5% by 2021. These factors are expected to have a negative impact on the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia and Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics Drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinsons Drugs, Anesthetics, Anti-Epileptics, Other CNS Drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics and COPD Drugs, Cough and Cold Preparations

The pharmaceutical active pharmaceutical ingredients (API) manufacturing market consists of sales of pharmaceutical active pharmaceutical ingredients and related services. Active pharmaceutical ingredients are used to produce drugs which treat various diseases such as cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others. Active pharmaceutical ingredient is a chemical which is responsible for the pharmacological activity in the living body and are used as a major base for preparation of drugs. The main therapy areas of pharmaceutical API manufacturing are cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs and other therapeutics uses. Cardiovascular diseases are a group of heart and blood vessel disorders. The various API type include chemical API and biological API that are used to produce innovative drugs, generic prescription, over-the-counter (OTC) drugs. The global pharmaceutical API manufacturing market size is expected to grow from $179.05 billion in 2021 to $195.29 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical API manufacturing market is expected to reach $250.66 billion in 2026 at a CAGR of 6.4%. The rise in aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in 2019, number of people over the age of 65 were 703 million, in 2050, the number of elderly people is expected to double to 1.5 billion. This led to increase demand for pharmaceutical drugs, significantly impacting the pharmaceutical API manufacturing market growth. Stringent regulations for approval of pharmaceutical drugs acts as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drugs regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drugs approvals, thereby negatively affecting the pharmaceuticals API manufacturing market. Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process which involves freezing the product, lowering pressure and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, an automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism which functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution. In January 2019, Bristol-Myers Squibb, a US-based company that discovers and manufactures biopharmaceutical products and drugs for cancer and other diseases acquired Celgene Corporation for $74 billion. With this acquisition, Bristol-Myers Squibb led to develop more innovative medicines and also result in a wider portfolio. Celgene Corporation, a US-based company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. Major players in the pharmaceutical API manufacturing market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, PfizerInc., Aurobindo Pharma, Novartis AG, Dr. Reddy's Laboratories, Merck & Co.Inc., BASF SE., Bayer Healthcare, Mylan N.V., Albemarle Corporation, Actavis plc, Hospira Inc., Ranbaxy Laboratories, Virbac, Zoetis, Heska Co., AbbVie Inc., AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi, Bristol-Myers Squibb, CiplaInc., and F. Hoffmann-La Roche Ltd. North America was the largest region in the pharmaceutical API manufacturing market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical API manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical API manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pharmaceutical api manufacturing market is segmented - 1) By Therapy Area: Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncology, Musculoskeletal Disorders, NSAIDs, Other Therapeutics Uses 2) By API Type: Chemical API, Biological API 3) By Drug Type: Innovative Drugs, Generic Prescription, Over-The-Counter (OTC) Drugs

The pharmaceutical contract development and manufacturing market consists of sales of pharmaceutical contract development and manufacturing products and related services. Some pharmaceutical companies outsource the manufacturing of products on contracts to focus on the R&D, marketing and branding of their products. The pharmaceutical contract development and manufacturing market consists of manufacturing firms who manufacture drugs and other pharmaceutical products for other pharmaceutical companies on contractual basis. The main types of pharmaceutical contract development and manufacturing organization (CMO) are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. The active pharmaceutical ingredient (API) manufacturing includes the manufacturing of the part of any drug that produces the desired effects. The various research phases include preclinical, phase I, phase II, phase III, phase IV. The different end use sectors include big pharmaceutical companies, generic pharmaceutical companies, small & medium-sized pharmaceutical companies. The global pharmaceutical contract development and manufacturing organization (CMO) market size is expected to grow from $114.36 billion in 2021 to $122.31 billion in 2022 at a compound annual growth rate (CAGR) of 7%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical CMO market is expected to reach $159.94 billion in 2026 at a CAGR of 6.9%. The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand in pharmaceutical contract development and manufacturing market. According to Alkermes plc, a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost cutting. The pharmaceutical contract development and manufacturing market is restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, according to a 2019 article by the Trade Promotion Council of India (TPCI) most of the pharmaceutical production units in India run at 30-40% of their capacity. Therefore, the under usage of capacity of production plant negatively affects the pharmaceutical contract development and manufacturing market. The companies in the pharmaceutical contract development and manufacturing market are investing towards acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition in order to expand their global market reach to meet the client needs, to increase their production capabilities while maintaining cost efficiencies and to get access to latest technology and new services. The high levels of merger and acquisition activities are resulting in consolidation of the contract service providers. For instance, according to a PricewaterhouseCoopers report, the largest M&A activity in the contract development and manufacturing organization sector was the deal between Thermo Fisher Scientific and Patheon, where the former acquired the latter for $7.2 billion. Also other important acquisitions were Thermo Fisher’s acquisition of Brammer Bio for $1.7 billion in 2019 and PAG’s acquisition of Acme Formulation Pvt Ltd., in 2021 for $145 million. In 2019, Permira Funds, a European equity firm acquired Cambrex Corporation for $2.4 billion. The acquisition is aimed to strengthen and expand the products and services offered by Cambrex Corporation towards the manufacturing of drugs. The Cambrex Corporation is a USA based contract development and manufacturing (CDMO) firm involved with the products and services related to small molecule active pharmaceutical ingredients. Major players in the pharmaceutical contract development and manufacturing market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V, Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd, AbbVie Inc., Consort Medical plc, Almac Group, Siegfried Holding AG, Evonik Industries AG and Vetter Pharma International GMBH. North America was the largest region in the pharmaceutical contract development and manufacturing market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (CMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical contract development and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK USA. The global pharmaceutical contract development and manufacturing organization market is segmented - 1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging 2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV 3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small and Medium-Sized Pharmaceutical Companies

The pharmaceutical excipients market consists of sales of pharmaceutical excipients and related services. The excipient is a substance, not an active pharmaceutical ingredient (API) that has been evaluated for safety, and intentionally added in a drug delivery system. Excipient's major roles are to protect, support, enhance stability, bioavailability, patient acceptability, and assist in the effectiveness. The market consists of revenue generated by the company’s manufacturing the pharmaceutical excipients by the sales of these excipients. The main types of products in pharmaceutical excipients are inorganic chemicals and organic chemicals. Pharmaceutical inorganic chemical is concerned with the manufacture, physical or chemical characteristics of substances, assay techniques, and applications of inorganic substances used as pharmaceutical aids, treatments, and diagnostics. The different functionalities include fillers and diluents, suspending and viscosity agents, coating agents, binders, flavouring agents and sweetners, disintegrants, colorants, lubricants and glidants, others and involves various formulations such as oral fromulation, topical formulation, parental formulation. The global pharmaceutical excipients market size is expected to grow from $8.13 billion in 2021 to $8.60 billion in 2022 at a compound annual growth rate (CAGR) of 5.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical excipient market is expected to reach $10.88 billion in 2026 at a CAGR of 6.0%. The global surge in the sale of generic drugs contributed to the growth of the pharmaceutical excipients market. Generic drugs are alternatives to the marketed brand name drug in the same dosage form, safety, strength, and route of administration and quality. According to India Brand Equity Foundation (IBEF), India is the largest provider of generic medicines, the country’s generic drugs account for 20% of the global generic drug exports. Indian pharmaceutical companies received 300 generic drug approvals in the USA. The surge in the demand for generic drugs drives the pharmaceutical excipients market. Concerns related to safety and quality are expected to limit the growth of the pharmaceutical excipients market. According to the Pharmaceutical Journal, there are certain complications in children with the use of pharmaceutical drugs with excipients. For instance, the colorants used in medicine as a coloring agent may lead to sensitivity reactions and hyperactive behaviour in children. Ethanol is another solvent that is widely used in an oral liquid formulation, the use of ethanol mixed medicine for children may have a risk of acute intoxication when overdose, and it may lead chronic toxicity with long term use. Concerns related to safety and quality are expected to limit the growth of the pharmaceutical excipients market. The increase in research and development in the pharmaceutical formulation to enhance the production process and product quality by using multi-functional excipients is a trend shaping the market. Excipients play a significant role in helping pharmaceutical manufacturers better support patients by increasing compliance and treatment effectiveness. For instance, Evonik’s newly launched EUDRAGIT FS 100 is a solid version of the existing EUDRAGIT FS 30 D. This new multi-functional version allows pharmaceutical companies to use the polymer in many new applications, such as hot-melt extrusion, solvent spray-drying, and solvent coating, which was impossible to achieve in past decades where only the aqueous version was available. In July 2021, Philip Morris International, a US based cigarette and tobacco manufacturing company acquired Fertin Pharma for $820m. Through this acquisition PMI will gain significant ability in developing, formulating, and marketing existing as well as new smoke-free platforms. Fertin Pharma is a Denmark based company that manufactures pharmaceutical excipients. Major players in the pharmaceutical excipients market are, Archer Daniels Midland Co., Associated British Foods, Dow Chemical Company, Evonik, Croda International Plc, Ashland, BASF SE, The Lubrizol Corporation, and Roquette Frères. North America is the largest region in the pharmaceutical excipients market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the pharmaceutical excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pharmaceutical excipients market is segmented - 1) By Functionality: Fillers and Diluents, Suspending and Viscosity Agents, Coating Agents, Binders, Flavoring Agents and Sweeteners, Disintegrants, Colorants, Lubricants and Glidants, Others 2) By Formulation Type: Oral Formulation, Topical Formulation, Parental Formulation 3) By Product: Inorganic Chemicals, Organic Chemicals

The pharmaceutical sterility testing market consists of sales of pharmaceutical sterility testing products and related services which are used to confirm that pharmaceutical products are free from the presence of viable microorganisms. Pharmaceutical sterility tests are procedures for checking the presence of microorganism in biological parenteral which are intended for human use. Pharmaceutical sterility testing is an important process in pharmaceuticals, medical equipment, and drugs manufacturing to assess the effectiveness of a sterilization process and is carried out at all levels of manufacturing to reduce the risk of product contamination. The main types of pharmaceutical sterility testing are in- house and outsourcing. The various types of tests include sterility testing, bioburden testing, bacterial endotoxin testing that are used to test sterile drugs, medical devices, biologics and therapeutics. An in vitro assay for detecting bacterial endotoxins is known as a bacterial endotoxin test. The bacterial endotoxin test detects bacterial endotoxins by lysing blood cells from horseshoe crabs. The different product used are instruments, kits and reagents, services. The global pharmaceutical sterility testing market size is expected to grow from $1.09 billion in 2021 to $1.19 billion in 2022 at a compound annual growth rate (CAGR) of 8.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical sterility testing market is expected to reach $1.68 billion in 2026 at a CAGR of 8.9%. An increase in the number of drug launches and rising investment in research and development (R&D) contributed to the growth of the pharmaceutical sterility testing market. Sterility is an important step in the manufacture of drugs to avoid product contamination and make the drugs free from any viable microorganism. According to a report published by Fierce Biotech shows that the top ten pharmaceutical companies invested over $82 billion in R&D in 2019. Additionally, according to Pharma and Annual Review 2019 report, 1,273 new drugs were launched in the global market in 2019, a 6.2% increase from the previous year. Increased emphasis on quality and sterility coupled with increasing R&D activities in the pharmaceutical sector and rising production and launch of drug and medical devices is driving the market. Companies in the pharmaceutical testing market are rising new pharmaceutical sterility testing products and services to enhance its product portfolio and increase its presence in the market. The companies are launching technologically superior outcomes and well-equipped services to utilize the growth potential of the rising pharmaceutical sterility market. For instance, in 2019, RSSL started a sterility testing service for pharmaceutical and medical device companies, which gives fast, active, and flexible test services. RSSL’s new sterility testing service includes two methods, membrane filtration for aqueous, ethanol, solution, and oil-based products and direct injection tests for non-soluble to determine the presence of infecting microorganisms in sterilized or aseptic drug products. Similarly, in October 2019, Alcami Corporation, a leading provider of a fully-integrated system for the pharmaceutical and biologics industries, launched a new rapid sterility offering, a service that leverages cutting-edge microbiological testing technology to give significantly faster-testing returns to customers. Major players in the pharmaceutical sterility testing market are Pacific Biolabs, STRERIS Corporation, Boston Analytical, Gibraltar Laboratories, Sartorius AG, SolviasAG, SGS AG, Toxikon Inc., Pace Analytical Services LLC, Charles River Laboratories International Inc, Nelson Laboratories Inc, Rapid Micro Biosystems Inc., BioMerieux, Merck KGaA, Wuxi AppTec, Sotera Health LLC, Dynalabs and Infinity. North America was the largest region in the pharmaceutical sterility testing market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical sterility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical sterility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pharmaceutical sterility testing market is segmented - 1) By Sample: Sterile Drugs, Medical Devices, Biologics and Therapeutics 2) By Product Type: Instruments, Kits and Reagents, Services 3) By Type: In-House, Outsourcing 4) By Test Type: Sterility Testing, Bioburden Testing, Bacterial Endotoxin Testing 5) By End-User: Compounding Pharmacies, Medical Devices Companies, Pharmaceutical Companies

The AI in pharma market consists of sales of AI in the pharma and related services that use an automated algorithm to perform tasks that traditionally rely on human intelligence. It can be useful in handling data and presenting results that encourage better decision-making and save human efforts, cost, and time. The market consists of revenue generated by artificial intelligence companies, which are applying in the pharmaceutical industry. Only goods and services traded between entities or sold to end consumers are included. The main technology types of artificial intelligence (AI) in pharma are context-aware processing, natural language processing, querying method, deep learning. Natural language processing is a a branch of artificial intelligence, concerned with giving computers the ability to understand text and spoken words in the same way that humans do. The various drugs produced are small molecule and large molecules that are used for diagnosis, clinical trial research, drug discovery, research and development and epidemic prediction. The global AI in pharma market size is expected to grow from $934.56 million in 2021 to $1,236.09 million in 2022 at a compound annual growth rate (CAGR) of 32.3%. The change in the AI in pharma market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2021. The market is expected to reach $3626.24 million in 2026 at a CAGR of 30.9%. The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in pharma market. To bring a new drug to the market takes on an average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in pharma market. Lack of skilled professionals may hamper the growth of AI in pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in pharma market. Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation. For instance, in September 2019, Novartis and Microsoft announced a multiyear alliance that will leverage data & Artificial Intelligence to transform how medicines are discovered, developed and commercialized. Further, Novartis also established an AI Innovation Lab to empower associates to use AI across their business. Therefore, companies operating in the market are continuously focusing on introducing new technologies to survive in the AI in pharma market. In April 2021, Charles River Laboratories, an American pharmaceutical company acquired Distributed Bio Inc. for $83 amount. The acquisition will increase success probability of Charles River Laboratories to deliver high quality, readily formattable antibody. Besides, the acquisition will expand the scientific capabilities of Charles River with innovative and large molecule discovery platform. Distributed Bio is a US-based next generation antibody discovery company with superhuman antibody libraries and integrated antibody technologies. Major players in the AI in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise Inc., Exscientia, Cyclica, NVIDIA Corporation, XtalPi Inc., BenevolentAI, Cloud Pharmaceuticals Inc, BERG LLC, Bayer, Pfizer, Recursion Pharmaceuticals Inc., and Bristol-Myers Squibb. North America was the largest region in the artificial intelligence in pharma market in 2021. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the AI in pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global AI in pharma market is segmented - 1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning 2) By Drug Type: Small Molecule, Large Molecules 3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction

Pharmaceutical Drugs And Biologics Logistics Market Definition

The pharmaceutical drugs and biologics market consists of sales of pharmaceutical drugs and biologics logistics services by entities (organizations, sole traders and partnerships) that provide pharmaceutical drugs and biologics logistics services. Pharmaceutical drugs and biologics logistics is the logistics of pharmaceutical and biologic drugs from the manufacturer to the end-user. It includes transportation, warehousing, inventory management and other logistics functions.